Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 144

1.

Sequential Validation of Blood-Based Protein Biomarker Candidates for Early-Stage Pancreatic Cancer.

Capello M, Bantis LE, Scelo G, Zhao Y, Li P, Dhillon DS, Patel NJ, Kundnani DL, Wang H, Abbruzzese JL, Maitra A, Tempero MA, Brand R, Firpo MA, Mulvihill SJ, Katz MH, Brennan P, Feng Z, Taguchi A, Hanash SM.

J Natl Cancer Inst. 2017 Apr 1;109(4). doi: 10.1093/jnci/djw266.

2.

A Plasma Biomarker Panel to Identify Surgically Resectable Early-Stage Pancreatic Cancer.

Balasenthil S, Huang Y, Liu S, Marsh T, Chen J, Stass SA, KuKuruga D, Brand R, Chen N, Frazier ML, Jack Lee J, Srivastava S, Sen S, McNeill Killary A.

J Natl Cancer Inst. 2017 Aug 1;109(8). doi: 10.1093/jnci/djw341.

3.

Validation of four candidate pancreatic cancer serological biomarkers that improve the performance of CA19.9.

Makawita S, Dimitromanolakis A, Soosaipillai A, Soleas I, Chan A, Gallinger S, Haun RS, Blasutig IM, Diamandis EP.

BMC Cancer. 2013 Sep 3;13:404. doi: 10.1186/1471-2407-13-404.

4.

Validation of biomarkers that complement CA19.9 in detecting early pancreatic cancer.

Chan A, Prassas I, Dimitromanolakis A, Brand RE, Serra S, Diamandis EP, Blasutig IM.

Clin Cancer Res. 2014 Nov 15;20(22):5787-95. doi: 10.1158/1078-0432.CCR-14-0289. Epub 2014 Sep 19.

5.

Periostin and CA242 as potential diagnostic serum biomarkers complementing CA19.9 in detecting pancreatic cancer.

Dong D, Jia L, Zhang L, Ma N, Zhang A, Zhou Y, Ren L.

Cancer Sci. 2018 Sep;109(9):2841-2851. doi: 10.1111/cas.13712. Epub 2018 Jul 24.

6.

Detection of early pancreatic ductal adenocarcinoma with thrombospondin-2 and CA19-9 blood markers.

Kim J, Bamlet WR, Oberg AL, Chaffee KG, Donahue G, Cao XJ, Chari S, Garcia BA, Petersen GM, Zaret KS.

Sci Transl Med. 2017 Jul 12;9(398). pii: eaah5583. doi: 10.1126/scitranslmed.aah5583.

7.

Serum osteopontin and tissue inhibitor of metalloproteinase 1 as diagnostic and prognostic biomarkers for pancreatic adenocarcinoma.

Poruk KE, Firpo MA, Scaife CL, Adler DG, Emerson LL, Boucher KM, Mulvihill SJ.

Pancreas. 2013 Mar;42(2):193-7. doi: 10.1097/MPA.0b013e31825e354d.

8.

Serum markers in patients with resectable pancreatic adenocarcinoma: macrophage inhibitory cytokine 1 versus CA19-9.

Koopmann J, Rosenzweig CN, Zhang Z, Canto MI, Brown DA, Hunter M, Yeo C, Chan DW, Breit SN, Goggins M.

Clin Cancer Res. 2006 Jan 15;12(2):442-6.

9.

Identification of IGFBP2 and IGFBP3 As Compensatory Biomarkers for CA19-9 in Early-Stage Pancreatic Cancer Using a Combination of Antibody-Based and LC-MS/MS-Based Proteomics.

Yoneyama T, Ohtsuki S, Honda K, Kobayashi M, Iwasaki M, Uchida Y, Okusaka T, Nakamori S, Shimahara M, Ueno T, Tsuchida A, Sata N, Ioka T, Yasunami Y, Kosuge T, Kaneda T, Kato T, Yagihara K, Fujita S, Huang W, Yamada T, Tachikawa M, Terasaki T.

PLoS One. 2016 Aug 31;11(8):e0161009. doi: 10.1371/journal.pone.0161009. eCollection 2016.

10.

Development of serum parameters panels for the early detection of pancreatic cancer.

Zhang P, Zou M, Wen X, Gu F, Li J, Liu G, Dong J, Deng X, Gao J, Li X, Jia X, Dong Z, Chen L, Wang Y, Tian Y.

Int J Cancer. 2014 Jun 1;134(11):2646-55. doi: 10.1002/ijc.28584. Epub 2013 Nov 19.

11.

Growth differentiation factor (GDF-15) concentration combined with Ca125 levels in serum is superior to commonly used cancer biomarkers in differentiation of pancreatic mass.

Hogendorf P, Durczyński A, Skulimowski A, Kumor A, Poznańska G, Strzelczyk J.

Cancer Biomark. 2018 Feb 14;21(3):505-511. doi: 10.3233/CBM-170203.

PMID:
29171983
12.

Serum cytokine biomarker panels for discriminating pancreatic cancer from benign pancreatic disease.

Shaw VE, Lane B, Jenkinson C, Cox T, Greenhalf W, Halloran CM, Tang J, Sutton R, Neoptolemos JP, Costello E.

Mol Cancer. 2014 May 20;13:114. doi: 10.1186/1476-4598-13-114.

13.

Identification of a novel serum biomarker for pancreatic cancer, C4b-binding protein α-chain (C4BPA) by quantitative proteomic analysis using tandem mass tags.

Sogawa K, Takano S, Iida F, Satoh M, Tsuchida S, Kawashima Y, Yoshitomi H, Sanda A, Kodera Y, Takizawa H, Mikata R, Ohtsuka M, Shimizu H, Miyazaki M, Yokosuka O, Nomura F.

Br J Cancer. 2016 Oct 11;115(8):949-956. doi: 10.1038/bjc.2016.295. Epub 2016 Sep 22.

14.

iTRAQ reveals candidate pancreatic cancer serum biomarkers: influence of obstructive jaundice on their performance.

Tonack S, Jenkinson C, Cox T, Elliott V, Jenkins RE, Kitteringham NR, Greenhalf W, Shaw V, Michalski CW, Friess H, Neoptolemos JP, Costello E.

Br J Cancer. 2013 May 14;108(9):1846-53. doi: 10.1038/bjc.2013.150. Epub 2013 Apr 11.

15.

Improved Pancreatic Adenocarcinoma Diagnosis in Jaundiced and Non-Jaundiced Pancreatic Adenocarcinoma Patients through the Combination of Routine Clinical Markers Associated to Pancreatic Adenocarcinoma Pathophysiology.

Ferri MJ, Saez M, Figueras J, Fort E, Sabat M, López-Ben S, de Llorens R, Aleixandre RN, Peracaula R.

PLoS One. 2016 Jan 25;11(1):e0147214. doi: 10.1371/journal.pone.0147214. eCollection 2016.

16.

Serum tumor antigen REG4 as a diagnostic biomarker in pancreatic ductal adenocarcinoma.

Takayama R, Nakagawa H, Sawaki A, Mizuno N, Kawai H, Tajika M, Yatabe Y, Matsuo K, Uehara R, Ono K, Nakamura Y, Yamao K.

J Gastroenterol. 2010;45(1):52-9. doi: 10.1007/s00535-009-0114-y. Epub 2009 Sep 30.

PMID:
19789838
17.

A Plasma-Derived Protein-Metabolite Multiplexed Panel for Early-Stage Pancreatic Cancer.

Fahrmann JF, Bantis LE, Capello M, Scelo G, Dennison JB, Patel N, Murage E, Vykoukal J, Kundnani DL, Foretova L, Fabianova E, Holcatova I, Janout V, Feng Z, Yip-Schneider M, Zhang J, Brand R, Taguchi A, Maitra A, Brennan P, Max Schmidt C, Hanash S.

J Natl Cancer Inst. 2019 Apr 1;111(4):372-379. doi: 10.1093/jnci/djy126.

18.

Comparison of circulating MMP-9, TIMP-1 and CA19-9 in the detection of pancreatic cancer.

Joergensen MT, Brünner N, De Muckadell OB.

Anticancer Res. 2010 Feb;30(2):587-92.

PMID:
20332475
19.

Identification of a Three-Biomarker Panel in Urine for Early Detection of Pancreatic Adenocarcinoma.

Radon TP, Massat NJ, Jones R, Alrawashdeh W, Dumartin L, Ennis D, Duffy SW, Kocher HM, Pereira SP, Guarner posthumous L, Murta-Nascimento C, Real FX, Malats N, Neoptolemos J, Costello E, Greenhalf W, Lemoine NR, Crnogorac-Jurcevic T.

Clin Cancer Res. 2015 Aug 1;21(15):3512-21. doi: 10.1158/1078-0432.CCR-14-2467.

20.

Serum dickkopf-1 is a novel serological biomarker for the diagnosis and prognosis of pancreatic cancer.

Han SX, Zhou X, Sui X, He CC, Cai MJ, Ma JL, Zhang YY, Zhou CY, Ma CX, Varela-Ramirez A, Zhu Q.

Oncotarget. 2015 Aug 14;6(23):19907-17.

Supplemental Content

Support Center